{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:05:40Z","timestamp":1783951540255,"version":"3.55.0"},"reference-count":16,"publisher":"Wiley","issue":"5-6","license":[{"start":{"date-parts":[[2006,7,20]],"date-time":"2006-07-20T00:00:00Z","timestamp":1153353600000},"content-version":"vor","delay-in-days":6409,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Pediatr. Oncol."],"published-print":{"date-parts":[[1989,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The relationship between salivary methotrexate (MTX) concentration and severity of oral mucositis after administration of MTX was investigated in six children with acute lymphoblastic leukemia. They received two administrations of MTX at 500 mg\/m<jats:sup>2<\/jats:sup> with one third given bolusly and the remainder by 24\u2010hour continuous infusion. No significant difference among patients or administration session was observed in serum MTX concentration. Detectable concentrations of salivary MTX (&gt; 0.01 \u03bcM) were observed during nine of the ten infusions. A concentration of 0.1 \u03bcM or more, apparently lasting at least 12 hours, was observed during one infusion and followed by severe mucositis. During two of the ten infusions for different patients, concentrations of 0.04 to 0.07 \u03bcM and 0.02 to 0.04 \u03bcM, apparently lasting at least 12 and 18 hours, respectively, were observed, followed by moderate mucositis. During the other seven infusions, either much shorter or no increase in salivary MTX concentration was observed, with only mild or no subsequent mucositis. Analysis by Kendall's rank method showed a statistical correlation between concentration at 6 hours of infusion and severity of oral mucositis. The findings suggest that the early secretion of MTX into saliva has a significant role in the development of oral mucositis in leukemic children.<\/jats:p>","DOI":"10.1002\/mpo.2950170514","type":"journal-article","created":{"date-parts":[[2008,9,24]],"date-time":"2008-09-24T14:31:23Z","timestamp":1222266683000},"page":"429-432","source":"Crossref","is-referenced-by-count":19,"title":["Oral mucositis and salivary methotrexate concentration in intermediate\u2010dose methotrexate therapy for children with acute lymphoblastic leukemia"],"prefix":"10.1002","volume":"17","author":[{"given":"Eiichi","family":"Ishii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin\u2010Ichi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsu","family":"Honjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisaji","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Kanemitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohji","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,7,20]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870701)60:1<5::AID-CNCR2820600103>3.0.CO;2-D"},{"key":"e_1_2_1_3_2","first-page":"201","volume-title":"Recent Advances in Cancer Treatment","author":"Djerassi I","year":"1977"},{"key":"e_1_2_1_4_2","first-page":"1007","article-title":"Intermediate dose methotrexate (IDM) in children with acute lymphoblastic leukemia (ALL). An update","volume":"30","author":"Freeman AI","year":"1985","journal-title":"Sangre"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00320346"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00258300"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb00923.x"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1902\/jop.1986.57.5.318"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1987.tb03208.x"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/clinchem\/22.7.1053","article-title":"Methotrexate in blood, urine, and cerebrospinal fluid of children receiving high doses by infusion","volume":"22","author":"Wang Y","year":"1976","journal-title":"Clin Chem"},{"key":"e_1_2_1_11_2","first-page":"55","article-title":"Technique for the measurement of methotrexate in biological samples","volume":"65","author":"Aherne GW","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00263903"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1984.tb03576.x"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0300-5712(78)90242-7"},{"key":"e_1_2_1_15_2","first-page":"147","article-title":"Cancer therapy by intraaterial methotrexate infusion. Protection of mucous membranes by topically applied citrovorum factor with hyaluronidase","volume":"21","author":"Stovner J","year":"1962","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_1_16_2","first-page":"1009","volume-title":"Applied Pharmacokinetics. Principles of therapeutic drug monitoring","author":"Evans WE","year":"1986"},{"key":"e_1_2_1_17_2","first-page":"575","article-title":"Absorption of leucovorin (NSC\u20103590) from a \u201cmouthwash\u201d","volume":"59","author":"Bruckner HW","year":"1975","journal-title":"Cancer Chemother Rep"}],"container-title":["Medical and Pediatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmpo.2950170514","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mpo.2950170514","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T08:41:07Z","timestamp":1693471267000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mpo.2950170514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,1]]},"references-count":16,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[1989,1]]}},"alternative-id":["10.1002\/mpo.2950170514"],"URL":"https:\/\/doi.org\/10.1002\/mpo.2950170514","archive":["Portico"],"relation":{},"ISSN":["0098-1532","1096-911X"],"issn-type":[{"value":"0098-1532","type":"print"},{"value":"1096-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989,1]]}}}